SEC Form 4 · accession 0001193125-26-269994
Vor Biopharma Inc. · VOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew David Levin
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 8:39 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817229
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2,F1 | $14.09 | Jun 11, 2026 | A | 57,162 | A | — | Jun 10, 2036 | Common stock | 57,162 | 57,162 | D |
Explanation of responses
- F1One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
- F2Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.